Vitrolife Past Earnings Performance
Past criteria checks 0/6
Vitrolife's earnings have been declining at an average annual rate of -71.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 24.9% per year.
Key information
-71.9%
Earnings growth rate
-71.3%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 24.9% |
| Return on equity | -29.0% |
| Net Margin | -107.0% |
| Next Earnings Update | 30 Jan 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Vitrolife makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,555 | -3,805 | 1,181 | 117 |
| 30 Jun 24 | 3,535 | -3,799 | 1,150 | 118 |
| 31 Mar 24 | 3,499 | -3,836 | 1,118 | 126 |
| 31 Dec 23 | 3,512 | -3,851 | 1,117 | 127 |
| 30 Sep 23 | 3,462 | 402 | 1,092 | 122 |
| 30 Jun 23 | 3,412 | 388 | 1,076 | 124 |
| 31 Mar 23 | 3,336 | 412 | 1,048 | 133 |
| 31 Dec 22 | 3,234 | 394 | 1,002 | 143 |
| 30 Sep 22 | 2,893 | 353 | 961 | 157 |
| 30 Jun 22 | 2,501 | 349 | 811 | 151 |
| 31 Mar 22 | 2,054 | 305 | 656 | 133 |
| 31 Dec 21 | 1,681 | 341 | 503 | 114 |
| 30 Sep 21 | 1,549 | 415 | 353 | 103 |
| 30 Jun 21 | 1,464 | 399 | 333 | 94 |
| 31 Mar 21 | 1,291 | 325 | 308 | 91 |
| 31 Dec 20 | 1,246 | 287 | 311 | 92 |
| 30 Sep 20 | 1,273 | 276 | 324 | 97 |
| 30 Jun 20 | 1,331 | 294 | 342 | 102 |
| 31 Mar 20 | 1,502 | 377 | 365 | 105 |
| 31 Dec 19 | 1,480 | 383 | 351 | 100 |
| 30 Sep 19 | 1,391 | 371 | 342 | 88 |
| 30 Jun 19 | 1,297 | 339 | 318 | 80 |
| 31 Mar 19 | 1,199 | 324 | 293 | 74 |
| 31 Dec 18 | 1,151 | 310 | 284 | 72 |
| 30 Sep 18 | 1,102 | 294 | 278 | 70 |
| 30 Jun 18 | 1,064 | 284 | 276 | 70 |
| 31 Mar 18 | 1,066 | 276 | 276 | 69 |
| 31 Dec 17 | 1,046 | 264 | 270 | 69 |
| 30 Sep 17 | 1,026 | 255 | 266 | 71 |
| 30 Jun 17 | 991 | 234 | 262 | 70 |
| 31 Mar 17 | 913 | 211 | 254 | 68 |
| 31 Dec 16 | 856 | 190 | 250 | 62 |
| 30 Sep 16 | 804 | 188 | 235 | 55 |
| 30 Jun 16 | 771 | 196 | 231 | 55 |
| 31 Mar 16 | 747 | 186 | 223 | 53 |
| 31 Dec 15 | 722 | 183 | 220 | 56 |
| 30 Sep 15 | 660 | 154 | 213 | 56 |
| 30 Jun 15 | 609 | 137 | 195 | 48 |
| 31 Mar 15 | 554 | 122 | 186 | 45 |
| 31 Dec 14 | 511 | 109 | 172 | 42 |
| 30 Sep 14 | 497 | 96 | 168 | 52 |
| 30 Jun 14 | 481 | 77 | 166 | 58 |
| 31 Mar 14 | 467 | 67 | 165 | 59 |
| 31 Dec 13 | 453 | 56 | 164 | 59 |
Quality Earnings: VTFN is currently unprofitable.
Growing Profit Margin: VTFN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VTFN is unprofitable, and losses have increased over the past 5 years at a rate of 71.9% per year.
Accelerating Growth: Unable to compare VTFN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTFN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: VTFN has a negative Return on Equity (-28.96%), as it is currently unprofitable.